nach oben

International Journal of Clinical Pharmacy

Erschienen in:

01.08.2014 | Review Article

Systematic review of severe acute liver injury caused by terbinafine

verfasst von: Jun Yan, Xiaolin Wang, Shengli Chen

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Background Terbinafine is an effective antimicrobial agent against dermatophytes, cryptococcus and other fungi. It is the preferred drug to treat onychomycosis. However, severe acute hepatitis from oral terbinafine administration has been recently reported. Aim To describe a representative case, and review the literature regarding the best evidence on treatment and prognosis of severe acute hepatitis caused by oral terbinafine. Methods The literature was searched for publications on severe hepatitis caused by terbinafine using MEDLINE, China Biology Medicine Disc, and the VIP Medical Information Resource System. Related references were searched manually. Results Seventeen English and three Chinese references of case reports were included after eliminating duplicate publications. No randomized control studies were found. Liver enzyme levels were found to have been increased significantly. Abdominal ultrasound demonstrated cholestasis. Conclusions Severe acute liver injury is a known, but unusual complication of terbinafine exposure. The prognosis is often good with appropriate treatment. Liver function assessment before treatment and periodic monitoring 4–6 weeks after initiation of treatment is recommended.

Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol. 1993;29:S50–4.PubMedCrossRef

Gupta AK, del Rosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol. 1998;23:64–7.PubMedCrossRef

Itraconazole, terbinafine possibly linked to liver failure. Am J Health Syst Pharm. 2001; 58: 1076.

Hepatic reactions with terbinafine. Aust Adverse Drug React Bull. 2008;27:2.

Xiao Z, Yanqing LI. Japan revised terbinafinewarning. Chin Pharmacist. 2004;7:479.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedCentralPubMedCrossRef

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.PubMedCrossRef

Lowe G, Green C, Jennings P. Hepatitis associated with terbinafine treatment. BMJ. 1993;306:248.PubMedCentralPubMedCrossRef

van ‘t Wout JW, Herrmann WA, De Vries RA, Stricker BH. Terbinafine-associated hepatic injury. J Hepatol. 1994;21:115–7.CrossRef

10.

Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC. Terbinafine-induced cholestatic liver disease. J Hepatol. 1996;24:753–6.PubMedCrossRef

11.

Dwyer CM, White MI, Sinclair TS. Cholestatic jaundice due to terbinafine. Br J Dermatol. 1997;136:976–7.PubMedCrossRef

12.

Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci. 1997;42:1486–8.PubMedCrossRef

13.

Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol. 1998;93:459–60.PubMedCrossRef

14.

Gupta AK, Porges AJ. Hypersensitivity syndrome reaction to oral terbinafine. Australas J Dermatol. 1998;39(3):171–2.PubMedCrossRef

15.

Agarwal K, Manas DM, Hudson M. Terbinafine and fulminant hepatic failure. N Engl J Med. 1999;340:1292–3.PubMedCrossRef

16.

Conjeevaram G, Vongthavaravat V, Sumner R, Koff RS. Terbinafine-induced hepatitis and pancytopenia. Dig Dis Sci. 2001;46:1714–6.PubMedCrossRef

17.

Chambers WM, Millar A, Jain S, Burroughs AK. Terbinafine-induced hepatic dysfunction. Eur J Gastroenterol Hepatol. 2001;13:1115–8.PubMedCrossRef

18.

Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated hepatotoxicity. Am J Med Sci. 2003;32:292–5.CrossRef

19.

Agca E, Akcay A, Simsek H. Ursodeoxycholic acid for terbinafine-induced toxic hepatitis. Ann Pharmacother. 2004;38:1088–9.PubMedCrossRef

20.

Xin S. Terbinafine hydrochloride caused by drug hepatic damage. Clin Med Chin. 2004;20:515.

21.

Xiaoqin LV, Zhang X. Terbinafine cause cholestasis hepatitis one case. Herald Med. 2006;25:593.

22.

Perveze Z, Johnson MW, Rubin RA, Sellers M, Zayas C, Jones JL, et al. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl. 2007;13:162–4.PubMedCrossRef

23.

Kim BS, Jang HS, Jwa SW, Jang BS, Kim MB, Oh CK, et al. Generalized pustular psoriasis and hepatic dysfunction associated with oral terbinafine therapy. J Korean Med Sci. 2007;22:167–9.PubMedCentralPubMedCrossRef

24.

Paredes AH, Lewis JH. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother. 2007;41:880–4.PubMedCrossRef

25.

Gendre G, Buclin T, Morard I, Fontannaz J, Berney JL. Terbinafine induced hepatitis with persistent cholestasis. Rev Med Suisse. 2008;4:736–9.PubMed

26.

Jing B, Yang Y. Terbinafine cause cholestasis hepatitis. ADRJ. 2008;10:284.

27.

Tausch I, Bräutigam M, Weidinger G, Jones TC. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. Br J Dermatol. 1997;136(5):737–42.PubMedCrossRef

28.

Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol. 2001;44(3):485–91.PubMedCrossRef

29.

Baran R, Feuilhade M, Combernale P, Datry A, Goettmann S, Pietrini P, et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol. 2000;142(6):1177–83.PubMedCrossRef

30.

De Backer M, De Vroey C, Lesaffre E, Scheys I, De Keyser P. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol. 1998;38(5 Pt 3):S57–63.PubMedCrossRef

31.

Chang CH, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med. 2007;120:791–8.PubMedCrossRef

32.

Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150:537–44.PubMedCrossRef

33.

Krob AH, Fleischer AB Jr, D’Agostino R Jr, Feldman SR. Terbinafine is more effective than itraconazole in treating toenail onychomycosis: results from a meta-analysis of randomized controlled trials. J Cutan Med Surg. 2003;7:306–11.PubMedCrossRef

34.

Casciano J, Amaya K, Doyle J, Arikian S, Shear N, Haspel M, Kahler K. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag Care. 2003;12:47–54.PubMed

35.

Haugh M, Helou S, Boissel JP, Cribier BJ. Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol. 2002;147:118–21.PubMedCrossRef

36.

Gupta AK. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J Am Podiatr Med Assoc. 2002;92:272–86.PubMedCrossRef

37.

Gupta AK, Lambert J. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. Int J Dermatol. 1999;38:S53–64.CrossRef

38.

De Doncker P. Itraconazole and terbinafine in perspective: from petri dish to patient. J Eur Acad Dermatol Venereol. 1999;12:S10–6.PubMed

39.

Marchetti A, Piech CT, McGhan WF, Neugut AI, Smith BT. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther. 1996;18:757–77.PubMedCrossRef

Titel: Systematic review of severe acute liver injury caused by terbinafine
verfasst von: Jun Yan
Xiaolin Wang
Shengli Chen
Publikationsdatum: 01.08.2014
Verlag: Springer Netherlands
Erschienen in: International Journal of Clinical Pharmacy / Ausgabe 4/2014
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-014-9969-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Client priorities and satisfaction with community pharmacies: the situation in Tehran

Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes

Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme

Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium

A qualitative study of pharmacists’ perceptions of, and recommendations for improvement of antibiotic use in Qatar